The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Executes the first project for developing and manufacturing a novel anticancer mAb
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Combination shows consistent benefit across prespecified post-progression outcomes
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
To accelerate the development of next-generation radioconjugates to treat cancer
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Sen spent a decade with Biocon and held various key roles,
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Subscribe To Our Newsletter & Stay Updated
